Issues & Trends

VIVOZON PHARMACEUTICAL Reports Third-Quarter Consolidated Revenue of 15.6 Billion Won… Operating Loss of 300 Million Won

Operating Loss Reduced by 97% Year-Over-Year

Kwon Oh Seok
2026-11-17 09:33:20
[Edaily Reporter Kwon Oh Seok ] VIVOZON PHARMACEUTICAL(082800)has come close to turning a quarterly profit, driven by increased sales of its flagship new drug and aggressive cost-cutting measures. Analysts say the company has demonstrated tangible improvements in its financial health by reducing its quarterly loss—which reached the 10 billion won range last year—to around 300 million won this year.
(Photo courtesy of VIVOZON PHARMACEUTICAL)

VIVOZON PHARMACEUTICAL announced on the 17th that it recorded consolidated revenue of 15.6 billion won and an operating loss of 300 million won for the third quarter of this year. Notably, the operating loss plummeted by 97.2% compared to the same period last year (10.2 billion won), bringing the company within sight of reaching the break-even point (BEP).
A review of this year’s quarterly profit and loss trends clearly reveals an improving profitability trend. The operating loss, which stood at 3 billion won in the first quarter, decreased to 1.9 billion won in the second quarter and further narrowed to 300 million won in the third quarter. Consequently, cumulative revenue for the first three quarters totaled 43 billion won, while the cumulative operating loss amounted to 5.2 billion won; the cumulative deficit also decreased by 66.1% compared to the same period last year (15.4 billion won).
The key driver of this earnings rebound is the non-opioid analgesic “Anapra.” Used to manage moderate-to-severe acute pain following surgery, Anapra is regarded as an alternative that alleviates concerns about the side effects of traditional opioid analgesics, and its supply to domestic medical institutions is rapidly increasing. Profitability has improved as the expansion of prescriptions for new drugs and the streamlining of the cost structure—including selling, general, and administrative expenses—have combined with the stable sales base of existing flagship products.
Building on its foothold in the domestic market, the company is also accelerating its overseas business. VIVOZON PHARMACEUTICAL recently secured an export contract with China for “LaraPang Tablets,” a colonoscopy laxative (bowel preparation), and is currently proceeding with the necessary procedures, aiming for the first shipment in the first quarter of 2027.
The company plans to establish a local distribution network using the Boao-Lucheng Medical Special Zone in Hainan Province—designated as a special zone for medical tourism and the introduction of new drugs in China—as a foothold. A representative from VIVOZON PHARMACEUTICAL emphasized, “Starting with securing a local supply chain for Larafang Tablets, we will also pursue entry into the global market for ‘Anapra,’ our core pipeline product, to expand the proportion of overseas sales.”

Economy

Corporation

IT·Science

Economy

[37th SRE][Survey] “Lego Land Nightmare Repeats”: Han Shin Rating Plummets to Last Place… Han Ki Rating Achieves First Place for Fifth Consecutive Year

Korea Ratings (KRI) took the top spot in the “Credit Rating Reliability” category of the 37th Edaily Survey of Credit Rating Experts (SRE), maintaining its number one position for the fifth consecutiv…
2026-11-17 10:00:08

Corporation

CJ CheilJedang Corp Installs Biodegradable Artificial Turf at Cheonan Soccer Stadium… First Implementation in a Domestic Sports Facility

CJ CheilJedang Corp. is taking steps to create a sustainable and safe sports environment by utilizing the biodegradable biomaterial “PHA” (polyhydroxyalkanoates). The company plans to introduce PHA-ba…
2026-11-17 09:50:47

IT·Science

AriBio Lab Soars...HLB Therapeutics Hits Lower Limit [K-Bio Pulse]

Korean pharmaceutical and biotech stocks saw sharply divergent performance on November 16 as investors reacted to clinical news. Corestem ChemOn hit the daily upper limit after clarifying its U.S. app…
2026-11-17 10:02:03